Introduction
============

Zika virus (ZIKV) is an emerging mosquito-transmitted flavivirus currently causing large epidemics in South and Central America as well as in the Caribbean, presenting a global public health emergency \[[@r1]\]. It is closely related to other human pathogenic members of the flavivirus family such as dengue virus (DENV), West Nile virus (WNV), Japanese encephalitis virus (JEV) and yellow fever virus (YFV). Besides their structural resemblance, most of these viruses share a partially overlapping geographical distribution, with tropical and subtropical regions representing the favourable environment of the main vector, mosquitos of the genus *Aedes* \[[@r2]\].

The diagnosis of ZIKV infections is increasingly relevant for European countries where, up to now, only a small number of travellers returning from endemic areas have contracted the virus \[[@r3]\]. However, there are concerns that ZIKV might be imported by infected individuals and spread through sexual transmission and via *Aedes* mosquitos that are endemic in parts of southern Europe.

The clinical symptoms associated with ZIKV infection include fever, rash, arthralgia, myalgia and conjunctivitis, and are normally self-limiting. The proportion of asymptomatic ZIKV infections is still unknown, but there is evidence that infection may go unrecognised in a considerable number of cases \[[@r1],[@r4]\]. In the acute phase, fever due to ZIKV infection is difficult to differentiate clinically from that due to DENV infections \[[@r5]\]. Chikungunya virus (CHIKV), belonging to the *Togaviridae* family, should also be considered in differential diagnostics, as it is transmitted by the same mosquito vector and circulates in the same regions \[[@r2]\]. The common distribution and similar clinical presentation, in combination with high variation in disease outcome of ZIKV-, DENV- and CHIKV-infected patients, highlight the need for specific and reliable diagnostic methods. Knowing the infecting virus can be of clinical relevance, for example, when ZIKV infection is suspected in women during pregnancy, which could result in fetal malformations, or in men who could transmit the virus sexually, or, in cases of CHIKV infection with prolonged arthralgias, where correct diagnosis can help avoid unnecessary rheumatological analysis.

The current ZIKV epidemic, particularly in Brazil, has revealed two potential complications in ZIKV infections, which were initially suspected during the 2007 outbreak in Micronesia \[[@r6]\]. Firstly, a large rise in the number of cases of Guillain--Barré syndrome (GBS), an autoimmune disease resulting from damage of peripheral-nerve myelin, was triggered by ZIKV infections \[[@r1],[@r7]\]. Secondly, a strong causative link was suggested between fetal abnormalities and ZIKV infection during early pregnancy, based on a 20-fold increase in newborn microcephaly in highly endemic regions in Brazil, followed by the first reports of ZIKV genome detection in amniotic fluid and fetal brain after intrauterine diagnosis of microcephaly \[[@r1],[@r8]-[@r10]\].

At present, diagnosis of ZIKV infections is challenging because the only specific tool is direct virus detection using nucleic acid-based testing (NAT), with ZIKV RNA detectable in serum up to 7 days after symptom onset and even longer in saliva, urine (about 20 days) and semen (\> 20 days) \[[@r6],[@r11]-[@r13]\]. Plaque-reduction neutralisation tests (PRNTs) can measure virus-specific neutralising antibodies, a fact that is relevant in regions where two or more flaviviruses co-occur. However, PRNTs do not discriminate between antibody classes and, especially in secondary flavivirus infections, cross-reactive neutralising antibodies may contribute to virus neutralisation \[[@r6],[@r14],[@r15]\], thus questioning the suitability of PRNTs for the confirmation of active infection. In addition, PRNTs are time-consuming, difficult to perform, not suitable for testing large panels, and therefore restricted to highly specialised laboratories. In contrast, ELISA-based measurement is a rapid, scalable and technically mature approach. IgM antibodies against flavivirus antigens are first produced 4 to 7 days after infection, and IgG antibodies appear a few days later. However, a major limitation of current ELISAs for diagnosing flaviviral infections is their extensive cross-reactivity within the *Flavivirus* genus \[[@r6]\].

The molecular organisation of flaviviruses is conserved. Virions consist of single-stranded positive RNA surrounded by an icosahedral capsid and envelope. The RNA encodes for a single polyprotein, which is processed into structural (C, prM, and E) and non-structural (NS1 to NS5) proteins \[[@r16]\]. Knowledge about NS1 is mainly derived from the well-studied flaviviruses (DENV, WNF, YFV), whereas little is known about NS1 from ZIKV. NS1 proteins (molecular mass 46--55 kDa) are present in two distinct variants \[[@r17]\]. Membrane-associated NS1 is mainly found as a dimer that interacts with intracellular membranes, such as the endoplasmic reticulum and vesicle packets, and with the cell surface \[[@r18],[@r19]\]. Secreted NS1 assembles into barrel-shaped hexamers consisting of three dimers \[[@r20],[@r21]\]. The NS1 function remains elusive, although roles in RNA replication \[[@r18]\], intracellular protein transport, virion release \[[@r22]\] and immunomodulatory activities \[[@r17]\] have been proposed. As reported for DENV and WNV, NS1 is secreted by infected cells into the bloodstream \[[@r23],[@r24]\], stimulating the immune system to produce high NS1 antibody titres. However, acute-phase release of ZIKV-NS1 into patient's serum has not yet been verified, and a ZIKV-NS1 antigen assay is currently not available \[[@r25]\]. Recombinant NS1 proteins were used in a multiplex serological protein microarray for the detection of anti-DENV, -WNV, and -JEV IgM and IgG, demonstrating high sensitivity and limited cross-reactivity, suggesting NS1 may represent an efficient antigenic substrate \[[@r26]\].

Recently, an ELISA based on recombinant ZIKV-NS1 has been developed \[[@r27]\]. Here, the diagnostic performance of this assay was examined using sera from returning travellers and patients from ZIKV-endemic areas with laboratory-confirmed ZIKV infection, potentially cross-reactive samples from patients with flaviviral and other infections, as well as control panels from blood donors of different ages and geographical origin.

Methods
=======

Human sera
----------

The study included serum samples from 27 patients who had tested positive for ZIKV RNA by reverse transcription PCR (RT-PCR); Group 1: travellers returning from endemic areas (n = 8); Group 2: residents in ZIKV-endemic areas (n = 19). On the basis of direct detection of the pathogen's genome, these cases were referred to as having RT-PCR-confirmed ZIKV infection. Samples from a further 85 patients had been pre-characterised by anti-ZIKV indirect immunofluorescence assay (IIFA; EUROIMMUN, Lübeck, Germany) based on whole virus antigen, showing reactivity for anti-ZIKV IgM and/or IgG; Group 3: travellers returning from endemic areas (n = 26); Group 4: residents in ZIKV-endemic areas (n = 59). Since false-positive results due to cross-reactivity of this IIFA cannot be excluded, these cases were referred to as having suspected ZIKV infection ([Table 1](#t1){ref-type="table"}).

###### Characteristics of patients with RT-PCR-confirmed (n = 27) and suspected (n = 85) Zika virus infection, study evaluating a novel NS1-based ELISA, Germany 2016

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case ID                                                                                          Age groups in years   Sex   Country of infection   Current/former residence      Sampling\   Phase of\      Clinical symptoms^b^   Diagnostic centre/\                                         ZIKV-RT-PCR assay/\                                                   ZIKV-RT-PCR result^c^   Virus neutralisation assay titre   IIFA IgM titre^d^   IIFA IgG titre^d^
                                                                                                                                                                                    Dpso        infection^a^                          provider of samples                                         performed at                                                                                                                                         
  ------------------------------------------------------------------------------------------------ --------------------- ----- ---------------------- ----------------------------- ----------- -------------- ---------------------- ----------------------------------------------------------- --------------------------------------------------------------------- ----------------------- ---------------------------------- ------------------- -------------------
  Group 1: RT-PCR-confirmed ZIKV infection, travellers returning from ZIKV-endemic areas (n = 8)                                                                                                                                                                                                                                                                                                                                                       

  1                                                                                                20--29                M     NA                     Non-endemic                   7           Active         Yes                    \                                                           RealStar Zika Virus RT-PCR (Altona Diagnostics, Hamburg, Germany)/\   **Pos**                 NA                                 **1:3,200**         **1:3,200**
                                                                                                                                                                                                                                      WHOCC, Hamburg, Germany\                                    WHOCC                                                                                                                                                

  2                                                                                                30--39                F     Haiti                  Non-endemic                   ≥ 4         Active         Yes                    **Pos**                                                     NA                                                                    **1:320**               **1:32,000**                                           

  3                                                                                                50--59                M     NA                     Non-endemic                   3           Initial        No                     **Pos**                                                     NA                                                                    NA                      NA                                                     

  4                                                                                                50--59                F     NA                     Non-endemic                   \< 4        Initial        NA                     **Pos**                                                     NA                                                                    **1:100**               **1:1,000**                                            

  5                                                                                                20--29                F     NA                     Non-endemic                   17          Active         NA                     \                                                           RealStar Zika Virus RT-PCR (Altona Diagnostics, Hamburg, Germany)/\   **Pos**                  **\> 1:640**                      NA                  NA
                                                                                                                                                                                                                                      ITM, Antwerp, Belgium\                                      ITM                                                                                                                                                  

  6                                                                                                40--49                M     NA                     Non-endemic                   11          Active         NA                     **Pos**                                                     **1:243**                                                             NA                      NA                                                     

  7                                                                                                0--9                  M     NA                     Non-endemic                   3           Initial        NA                     **Pos**                                                     NA                                                                    NA                      NA                                                     

  8                                                                                                20--29                F     NA                     Non-endemic                   11          Active         NA                     **Pos**                                                     **1:788**                                                             NA                      NA                                                     

  Group 2: RT-PCR-confirmed ZIKV infection, residents in ZIKV-endemic areas (n = 19)                                                                                                                                                                                                                                                                                                                                                                   

  1                                                                                                60--69                F     Suriname               The Netherlands/Suriname^e^   3           Initial        NA                     \                                                           In-house Zika RT-PCR/AMC                                              **Pos**                 NA                                 NA                  NA
                                                                                                                                                                                                                                      AMC, Amsterdam,\                                                                                                                                                                                                 
                                                                                                                                                                                                                                      the Netherlands\                                                                                                                                                                                                 

  2                                                                                                50--59                M     Suriname               The Netherlands/Suriname^e^   5           Initial        NA                     **Pos**                                                     NA                                                                    NA                      NA                                                     

  3                                                                                                40--49                F     Suriname               The Netherlands/Suriname^e^   11          Active         NA                     **Pos**                                                     NA                                                                    NA                      NA                                                     

  4                                                                                                40--49                M     Suriname               The Netherlands/Suriname^e^   9           Active         NA                     **Pos**                                                     NA                                                                    NA                      NA                                                     

  5                                                                                                50--59                F     Suriname               The Netherlands/Suriname^e^   6           Active         NA                     **Pos**                                                     NA                                                                    NA                      NA                                                     

  6                                                                                                50--59                M     Suriname               The Netherlands/Suriname^e^   6           Active         NA                     **Pos**                                                     NA                                                                    NA                      NA                                                     

  7                                                                                                50--59                F     Suriname               The Netherlands/Suriname^e^   53          Late           NA                     **Pos**                                                     NA                                                                    NA                      NA                                                     

  8                                                                                                50--59                F     Suriname               The Netherlands/Suriname^e^   17          Active         NA                     **Pos**                                                     NA                                                                    NA                      NA                                                     

  9                                                                                                60--69                F     Suriname               The Netherlands/Suriname^e^   24          Late           NA                     **Pos**                                                     NA                                                                    NA                      NA                                                     

  10                                                                                               70--79                M     Suriname               The Netherlands/Suriname^e^   6           Active         NA                     **Pos**                                                     NA                                                                    NA                      NA                                                     

  11                                                                                               0--9                  M     Dominican Republic     The Netherlands               1           Initial        NA                     **Pos**                                                     NA                                                                    NA                      NA                                                     

  12                                                                                               50--59                F     Dominican Republic     Dominican Republic            20          Active         Yes                    \                                                           Trioplex real-time RT-PCR (CDC, Atlanta, Georgia, US)/CDC             **Pos**                 NA                                 0                   **1:32,000**
                                                                                                                                                                                                                                      Boca Biolistics, Coconut Creek, Florida, US\                                                                                                                                                                     

  13                                                                                               50--59                F     Dominican Republic     Dominican Republic            31          Late           Yes                    **Pos**                                                     NA                                                                    **1:100**               **1:32,000**                                           

  14                                                                                               20--29                M     Colombia               Colombia                      3           Initial        Yes                    \                                                           Trioplex real-time RT-PCR (CDC, Atlanta, Georgia, US)/CDC             **Pos**                 NA                                 0                   **1:1,000**
                                                                                                                                                                                                                                      Allied Research Society, Miami Lakes, Florida, US\                                                                                                                                                               

  15                                                                                               40--49                F     Colombia               Colombia                      5           Initial        Yes                    **Pos**                                                     NA                                                                    0                       **1:1,000**                                            

  16                                                                                               50--59                F     Colombia               Colombia                      4           Initial        Yes                    **Pos**                                                     NA                                                                    **1:10**                **1:3,200**                                            

  17                                                                                               10--19                M     Colombia               Colombia                      3           Initial        Yes                    **Pos**                                                     NA                                                                    0                       **1:3,200**                                            

  18                                                                                               20--29                F     Colombia               Colombia                      6           Active         Yes                    \                                                           RealStar Zika Virus RT-PCR (Altona Diagnostics, Hamburg, Germany)/\   **Pos**                 NA                                 **1:3,200**         **1:32,000**
                                                                                                                                                                                                                                       Biomex GmbH, Heidelberg, Germany \                         Altona Diagnostics                                                                                                                                   

  19                                                                                               10--19                M     Colombia               Colombia/US                   15          Active         Yes                    Trioplex real-time RT-PCR (CDC, Atlanta, Georgia, US)/CDC   **Pos**                                                               NA                      **1:10**                           **1:32,000**        

  Group 3: Suspected ZIKV infection, travellers returning from ZIKV-endemic areas (n = 26)                                                                                                                                                                                                                                                                                                                                                             

  1                                                                                                NA                    NA    NA                     Non-endemic                   NA          NA             NA                     WHOCC, Hamburg, Germany                                     NA                                                                    NA                      NA                                 **1:3,200**         **1:10,000**

  2                                                                                                NA                    NA    NA                     Non-endemic                   NA          NA             NA                     NA                                                          NA                                                                    **1:1,000**             **1:10,000**                                           

  3                                                                                                NA                    NA    NA                     Non-endemic                   NA          NA             NA                     NA                                                          NA                                                                    **1:3,200**             **1:10,000**                                           

  4                                                                                                NA                    NA    Brazil                 Non-endemic                   NA          NA             NA                     NA                                                          NA                                                                    **1:1,000**             **1:32,000**                                           

  5                                                                                                NA                    NA    Brazil                 Non-endemic                   NA          NA             NA                     NA                                                          NA                                                                    **1:1,000**             **1:3,200**                                            

  6                                                                                                NA                    NA    Brazil                 Non-endemic                   NA          NA             NA                     NA                                                          NA                                                                    **1:3,200**             **1:10,000**                                           

  7                                                                                                NA                    NA    Brazil                 Non-endemic                   NA          NA             NA                     NA                                                          NA                                                                    **1:100**               \< 1:100                                               

  8                                                                                                NA                    NA    NA                     Non-endemic                   NA          NA             NA                     NA                                                          NA                                                                    **1:1,000**             **1:100**                                              

  9                                                                                                NA                    NA    NA                     Non-endemic                   NA          NA             NA                     NA                                                          NA                                                                    **1:320**               **1:10,000**                                           

  10                                                                                               NA                    NA    NA                     Non-endemic                   NA          NA             NA                     NA                                                          NA                                                                    **1:320**               **1:32,000**                                           

  11                                                                                               NA                    NA    Brazil                 Non-endemic                   19          Active         Yes                    NA                                                          NA                                                                    **1:320**               **1:10,000**                                           

  12                                                                                               NA                    NA    Brazil                 Non-endemic                   NA          NA             NA                     NA                                                          NA                                                                    **1:100**               **1:100,000**                                          

  13                                                                                               NA                    NA    Brazil                 Non-endemic                   NA          NA             NA                     NA                                                          NA                                                                    **1:1,000**             **1:320**                                              

  14                                                                                               NA                    NA    Brazil                 Non-endemic                   NA          NA             NA                     NA                                                          NA                                                                    **1:320**               **1:3,200**                                            

  15                                                                                               NA                    NA    Brazil                 Non-endemic                   NA          NA             NA                     NA                                                          NA                                                                    **1:320**               **1:1,000**                                            

  16                                                                                               NA                    NA    Brazil                 Non-endemic                   NA          NA             NA                     NA                                                          NA                                                                    **1:1,000**             **1:10,000**                                           

  17                                                                                               NA                    NA    Brazil                 Non-endemic                   NA          NA             NA                     NA                                                          NA                                                                    **1:320**               **1:10,000**                                           

  18                                                                                               NA                    NA    NA                     Non-endemic                   32          Late           NA                     NA                                                          NA                                                                    **1:100**               **1:32,000**                                           

  19                                                                                               NA                    NA    Colombia               Non-endemic                   45          Late           NA                     NA                                                          NA                                                                    **1:100**               **1:3,200**                                            

  20                                                                                               NA                    NA    NA                     Non-endemic                   NA          NA             NA                     NA                                                          NA                                                                    **1:1,000**             **1:10,000**                                           

  21                                                                                               NA                    NA    Denmark                Non-endemic                   NA          NA             NA                     NA                                                          NA                                                                    **1:100**               **1:32,000**                                           

  22                                                                                               NA                    NA    NA                     Non-endemic                   NA          NA             NA                     NA                                                          NA                                                                    **1:3,200**             **1:32,000**                                           

  23                                                                                               NA                    NA    Colombia               Non-endemic                   NA          NA             NA                     NA                                                          NA                                                                    **1:100**               **1:10,000**                                           

  24                                                                                               NA                    NA    Brazil                 Non-endemic                   NA          NA             NA                     NA                                                          NA                                                                    **1:320**               **1:32,000**                                           

  25                                                                                               NA                    NA    Brazil                 Non-endemic                   NA          NA             NA                     NA                                                          NA                                                                    **1:320**               **1:32,000**                                           

  26                                                                                               NA                    NA    Colombia               Non-endemic                   15          Active         NA                     NA                                                          NA                                                                    **1:3,200**             **1:10,000**                                           

  Group 4: Suspected ZIKV infection, residents in ZIKV-endemic areas (n = 59)                                                                                                                                                                                                                                                                                                                                                                          

  1                                                                                                30--39                F     Colombia               Colombia                      6           Active         Yes                    Allied Research Society, Miami Lakes, Florida, US           NA                                                                    NA                      NA                                 **1:1,000**         **1:320,000**

  2                                                                                                20--29                M     Colombia               Colombia                      8           Active         Yes                    NA                                                          NA                                                                    **1:100**               **1:1,000**                                            

  3                                                                                                30--39                F     Colombia               Colombia                      11          Active         Yes                    NA                                                          NA                                                                    0                       **1:1,000**                                            

  4                                                                                                40--49                M     Colombia               Colombia                      14          Active         Yes                    NA                                                          NA                                                                    **1:3,200**             **1:320,000**                                          

  5                                                                                                30--39                F     Colombia               Colombia                      17          Active         Yes                    NA                                                          NA                                                                    **1:3,200**             **1:320,000**                                          

  6                                                                                                80--89                M     Colombia               Colombia                      20          Active         Yes                    NA                                                          NA                                                                    **1:320**               **1:320,000**                                          

  7                                                                                                50--59                F     Colombia               Colombia                      23          Late           Yes                    NA                                                          NA                                                                    **1:320**               **1:10,000**                                           

  8                                                                                                30--39                M     Colombia               Colombia                      30          Late           Yes                    NA                                                          NA                                                                    **1:3,200**             **1:320,000**                                          

  9                                                                                                40--49                F     Colombia               Colombia                      49          Late           Yes                    NA                                                          NA                                                                    **1:100**               **1:10,000**                                           

  10                                                                                               10--19                F     Colombia               Colombia                      54          Late           Yes                    NA                                                          NA                                                                    **1:10**                **1:1,000**                                            

  11                                                                                               50--59                F     Colombia               Colombia                      6           Active         Yes                    NA                                                          NA                                                                    0                       **1:3,200**                                            

  12                                                                                               40--49                F     Colombia               Colombia                      4           Initial        Yes                    NA                                                          NA                                                                    0                       **1:1,000**                                            

  13                                                                                               10--19                M     Colombia               Colombia                      66          Late           Yes                    NA                                                          NA                                                                    0                       **1:32,000**                                           

  14                                                                                               40--49                F     Colombia               Colombia                      68          Late           Yes                    NA                                                          NA                                                                    **1:10**                **1:32,000**                                           

  15                                                                                               50--59                F     NA                     Colombia                      70          Late           Yes                    NA                                                          NA                                                                    0                       **1:32,000**                                           

  16                                                                                               40--49                F     NA                     Colombia                      2           Initial        Yes                    NA                                                          NA                                                                    0                       **1:10,000**                                           

  17                                                                                               20--29                F     Colombia               Colombia                      7           Active         Yes                    NA                                                          NA                                                                    **1:100**               **1:320,000**                                          

  18                                                                                               50--59                F     NA                     Colombia                      4           Initial        Yes                    NA                                                          NA                                                                    **1:100**               **1:100,000**                                          

  19                                                                                               40--49                M     Colombia               Colombia                      3           Initial        Yes                    NA                                                          NA                                                                    **1:10,000**            **1:32,000**                                           

  20                                                                                               40--49                F     Colombia               Colombia                      4           Initial        Yes                    NA                                                          NA                                                                    **1:32**                **1:32,000**                                           

  21                                                                                               30--39                M     Colombia               Colombia                      4           Initial        Yes                    NA                                                          NA                                                                    **1:32**                **1:32,000**                                           

  22                                                                                               40--49                F     Colombia               Colombia                      4           Initial        Yes                    NA                                                          NA                                                                    0                       **1:100,000**                                          

  23                                                                                               30--39                M     Colombia               Colombia                      4           Initial        Yes                    NA                                                          NA                                                                    0                       **1:32,000**                                           

  24                                                                                               20--29                F     Colombia               Colombia                      5           Initial        Yes                    NA                                                          NA                                                                    **1:10**                **1:10,000**                                           

  25                                                                                               40--49                F     Colombia               Colombia                      5           Initial        Yes                    NA                                                          NA                                                                    **1:1,000**             **1:100,000**                                          

  26                                                                                               30--39                F     Colombia               Colombia                      3           Initial        Yes                    NA                                                          NA                                                                    0                       **1:3,200**                                            

  27                                                                                               40--49                F     Colombia               Colombia                      4           Initial        Yes                    NA                                                          NA                                                                    0                       **1:32,000**                                           

  28                                                                                               20--29                F     Colombia               Colombia                      3           Initial        Yes                    NA                                                          NA                                                                    0                       **1:320**                                              

  29                                                                                               50--59                F     Colombia               Colombia                      4           Initial        Yes                    NA                                                          NA                                                                    0                       **1:10,000**                                           

  30                                                                                               20--29                F     Colombia               Colombia                      3           Initial        Yes                    NA                                                          NA                                                                    **1:32**                **1:10,000**                                           

  31                                                                                               30--39                F     Colombia               Colombia                      3           Initial        Yes                    Biomex GmbH, Heidelberg, Germany                            NA                                                                    NA                      NA                                 0                   **1:32,000**

  32                                                                                               20--29                F     Colombia               Colombia                      4           Initial        Yes                    NA                                                          NA                                                                    **1:100**               **1:32,000**                                           

  33                                                                                               10--19                F     Colombia               Colombia                      9           Active         Yes                    NA                                                          NA                                                                    **1:100**               **1:32,000**                                           

  34                                                                                               20--29                F     Colombia               Colombia                      12          Active         Yes                    NA                                                          NA                                                                    0                       **1:32,000**                                           

  35                                                                                               10--19                F     Colombia               Colombia                      20          Active         Yes                    NA                                                          NA                                                                    **1:100**               **1:10,000**                                           

  36                                                                                               20--29                F     Colombia               Colombia                      27          Late           Yes                    NA                                                          NA                                                                    **1:320**               **1:10,000**                                           

  37                                                                                               30--39                F     Colombia               Colombia                      36          Late           Yes                    NA                                                          NA                                                                    **1:10**                **1:32,000**                                           

  38                                                                                               10--19                F     Colombia               Colombia                      56          Late           Yes                    NA                                                          NA                                                                    **1:100**               **1:10,000**                                           

  39                                                                                               30--39                F     Colombia               Colombia                      67          Late           Yes                    NA                                                          NA                                                                    **1:10**                **1:32,000**                                           

  40                                                                                               10--19                F     Colombia               Colombia                      2           Initial        Yes                    Allied Research Society, Miami Lakes, Florida, US           NA                                                                    NA                      NA                                 0                   **1:10,000**

  41                                                                                               30--39                F     Colombia               Colombia                      5           Initial        Yes                    NA                                                          NA                                                                    **1:320**               **1:10,000**                                           

  42                                                                                               20--29                F     Colombia               Colombia                      6           Active         Yes                    NA                                                          NA                                                                    **1:100**               **1:10,000**                                           

  43                                                                                               20--29                F     Colombia               Colombia                      8           Active         Yes                    NA                                                          NA                                                                    **1:100**               **1:32,000**                                           

  44                                                                                               30--39                F     Colombia               Colombia                      15          Active         Yes                    NA                                                          NA                                                                    0                       **1:10,000**                                           

  45                                                                                               20--29                F     Colombia               Colombia                      21          Late           Yes                    NA                                                          NA                                                                    **1:10**                **1:100,000**                                          

  46                                                                                               20--29                F     Colombia               Colombia                      29          Late           Yes                    NA                                                          NA                                                                    **1:320**               **1:32,000**                                           

  47                                                                                               20--29                F     Colombia               Colombia                      38          Late           Yes                    NA                                                          NA                                                                    **1:1,000**             **1:320,000**                                          

  48                                                                                               10--19                F     Colombia               Colombia                      50          Late           Yes                    NA                                                          NA                                                                    **1:10**                **1:10,000**                                           

  49                                                                                               20--29                F     Colombia               Colombia                      88          Late           Yes                    NA                                                          NA                                                                    0                       **1:1,000**                                            

  50                                                                                               40--49                F     Colombia               Colombia                      2           Initial        Yes                    NA                                                          NA                                                                    0                       **1:3,200**                                            

  51                                                                                               20--29                M     Colombia               Colombia                      5           Initial        Yes                    NA                                                          NA                                                                    **1:1,000**             **1:32,000**                                           

  52                                                                                               30--39                F     Colombia               Colombia                      6           Active         Yes                    NA                                                          NA                                                                    0                       **1:1,000**                                            

  53                                                                                               20--29                M     Colombia               Colombia                      8           Active         Yes                    NA                                                          NA                                                                    0                       **1:10,000**                                           

  54                                                                                               30--39                F     Colombia               Colombia                      15          Active         Yes                    NA                                                          NA                                                                    **1:320**               **1:320,000**                                          

  55                                                                                               30--39                M     Colombia               Colombia                      21          Late           Yes                    NA                                                          NA                                                                    **1:100**               **1:32,000**                                           

  56                                                                                               40--49                M     Colombia               Colombia                      29          Late           Yes                    NA                                                          NA                                                                    **1:32,000**            **1:32,000**                                           

  57                                                                                               40--49                F     Colombia               Colombia                      38          Late           Yes                    NA                                                          NA                                                                    0                       **1:320**                                              

  58                                                                                               50--59                F     Colombia               Colombia                      50          Late           Yes                    NA                                                          NA                                                                    0                       **1:100,000**                                          

  59                                                                                               50--59                M     Colombia               Colombia                      85          Late           Yes                    NA                                                          NA                                                                    0                       **1:32,000**                                           
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AMC: Academic Medical Center; CDC: Centers for Disease Control and Prevention; dpso: days post symptom onset; F: female; IIFA: indirect immunofluorescence assay; ITM: Institute of Tropical Medicine, M: male; NA: not available; NS: non-structural protein; Pos: positive; US: United States; WHOCC: World Health Organization Collaborating Centre (for Arbovirus and Haemorrhagic Fever Reference and Research); ZIKV: Zika virus.

^a^ Phase of infection at the time of sample collection: initial phase: ≤ 5 dpso; active phase: 6 to 20 dpso; late phase: \> 20 dpso \[[@r28]\].

^b^ Fever, skin rash, joint pain, myalgia, headache, conjunctivitis, eye pain, diarrhoea and malaise.

^c^ ZIKV-RT-PCR results can also refer to serum or urine samples taken at an earlier date than the samples used for anti-ZIKV serological testing.

^d^ IIFA was performed at EUROIMMUN, Lübeck, Germany, using the Anti-Zika Virus IIFA test kit (EUROIMMUN). Cut-off IgM: ≥ 1:10; IgG: ≥ 1:100.

^e^ Sera from Dutch residents who were born and raised in Suriname and/or had visited their country of origin occasionally.

Classification into three stages of ZIKV infection was according to the Pan American Health Organization (PAHO) /World Health Organization (WHO) recommendations on ZIKV surveillance in the Americas \[[@r28]\]: ≤ 5 days post symptom onset, initial stage; 6--20 days post symptom onset, active stage; \> 20 days post symptom onset, late stage. Samples from travellers returning from endemic areas were provided by the diagnostic institutes (listed in [Table 1](#t1){ref-type="table"}) to which they had been sent for routine diagnostic testing. Samples from patients residing in Latin America (i.e. Dominican Republic and Colombia) were purchased from Boca Biolistics (Coconut Creek, Florida, United States (United States (US)), Allied Research Society (Miami Lakes, Florida, US) and Biomex GmbH (Heidelberg, Germany). As confirmed by these institutes and companies, written informed consent had been obtained from all patients, and there were no legal or ethical restrictions to using the samples.

To evaluate cross-reactivity, samples were used from 252 patients with either a post-YFV vaccination status (n = 12), or with other flaviviral (DENV = 93; WNV = 34, JEV = 25), non-flaviviral (CHIKV = 19) and *Plasmodium* spp. (PLAS: n = 69) infections. In samples from DENV-infected patients, the confirmation of DENV as the infectious agent was based on NS1 antigen detection \[[@r28]\]. Sera from 1,015 healthy individuals (pregnant women, blood donors and children) living in flavivirus-endemic and non-endemic areas served as negative controls. Pre-characterisation data for all control cohorts are reported in [Table 2](#t2){ref-type="table"}. To the best of the authors' knowledge, none of these samples were analysed in previous studies.

###### Characteristics of control cohorts, study evaluating a novel NS1-based ELISA, Germany 2016

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cohort                                                            n     Origin of sample donors                                                                                                     Type                                                                                                                                   Diagnostic centre\                                                             Sample receipt                                                        Pre‑characterisation                                                      
                                                                                                                                                                                                                                                                                                                                             (provider of samples)                                                                           
  ----------------------------------------------------------------- ----- ------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------ ---------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Flavivirus infection or vaccination**                                                                                                                                                                                                                                                                                                                                                                                                    

  DENVa\                                                            47    Germany, Italy                                                                                               Returning travellers from endemic areas with DENV infection (contracted e.g. in Brazil, Bali, Thailand, Laos, Philippines, India, Cambodia, Taiwan)   MVZ Diamedes GmbH Bielefeld, Germany;\                                         2011--2014       • Panbio or BIO-RAD DENV-NS1 ELISA^a,b^: 47/47 (100%) DENV-NS1 positive\
  (high IgM)                                                                                                                                                                                                                                                                                                                                 University of Bologna, Bologna, Italy;\                                                         • DENV-RT-PCR (only 8/47 tested)^b^: n = 4 subtype DENV-1, n = 2 subtype DENV-2, n = 2 subtype DENV-3\
                                                                                                                                                                                                                                                                                                                                             WHOCC, Hamburg, Germany                                                                         • EUROIMMUN Anti-DENV ELISA (IgM, IgG)^c^: 40/47 (85%) anti-DENV IgM positive, 30/47 (64%) anti-DENV IgG positive, 37/47 (79%) anti-DENV IgM ratio ≥ 3.0, 10/47 (21%) anti-DENV IgM ratio \< 3.0, anti-DENV IgM median ratio = 3.9

  DENVb\                                                            46    Germany, Italy                                                                                               Returning travellers from endemic areas with DENV infection (contracted e.g. in Brazil, Bali, Thailand, Laos, Philippines, India, Cambodia, Taiwan)   MVZ Diamedes GmbH Bielefeld, Germany;\                                         2011--2014       • DENV-NS1 ELISA^a,b^: 46/46 (100%) DENV-NS1 positive\
  (high IgG)                                                                                                                                                                                                                                                                                                                                 University of Bologna, Bologna, Italy                                                           • DENV-RT-PCR (only 1/46 tested)^b^: n = 1 subtype DENV-4\
                                                                                                                                                                                                                                                                                                                                                                                                                                             • EUROIMMUN Anti-DENV ELISA (IgM, IgG)^c^: 35/46 (76%) anti-DENV IgM positive, 40/46 (87%) anti-DENV IgG positive, 37/46 (80%) anti-DENV IgG ratio ≥ 3.0, 9/46 (20%) anti-DENV IgG ratio \< 3.0, • anti-DENV IgG median ratio = 3.9

  YFV                                                               12    France                                                                                                       Individuals vaccinated against YFV                                                                                                                    Cerba Specimen Services, Saint-Ouen l\'Aumône, France                          2015             • YFV seroneutralisation test^d^: 12/12 (100%) anti-YFV positive\
                                                                                                                                                                                                                                                                                                                                                                                                                                             • EUROIMMUN Anti-WNV ELISA (IgM, IgG)^c^: 0/12 (0%) anti-WNV IgM positive, 0/12 (0%) anti-WNV IgG positive\
                                                                                                                                                                                                                                                                                                                                                                                                                                             • EUROIMMUN Anti-CHIKV ELISA (IgM, IgG)^c^: 0/12 (0%) anti-CHIKV IgM positive, 1/12 (8%) anti-CHIKV IgG positive

  WNV                                                               34    US                                                                                                           Patients from endemic areas with WNV infection                                                                                                        MAYO Clinic, Scottsdale, Arizona, US                                           2014             • WNV PRNT^e^: 34/34 (100%) anti-WNV positive\
                                                                                                                                                                                                                                                                                                                                                                                                                                             • EUROIMMUN Anti-WNV ELISA (IgM, IgG)^c^: 23/34 (68%) anti-WNV IgM positive, 26/34 (76%) anti-WNV IgG positive

  JEV                                                               25    Vietnam                                                                                                      Patients from endemic areas with JEV infection                                                                                                        National Hospital of Tropical Disease, Hanoi, Vietnam                          2016             • DRG JE IgM capture ELISA^f^: 25/25 (100%) anti-JEV IgM positive\
                                                                                                                                                                                                                                                                                                                                                                                                                                             • EUROIMMUN Anti-JEV ELISA (IgM, IgG)^c^: 25/25 (100%) anti-JEV IgM positive, 19/25 (76%) anti-JEV IgG positive

  **Non-flavivirus infection**                                                                                                                                                                                                                                                                                                                                                                                                               

  CHIKV                                                             19    Réunion                                                                                                      Patients from endemic areas with CHIKV infection                                                                                                      Cerba Specimen Services, Saint-Ouen l'Aumône, France                           2015             • CHIKV VRP neutralisation test^g^: 19/19 (100%) anti-CHIKV positive\
                                                                                                                                                                                                                                                                                                                                                                                                                                             • EUROIMMUN Anti-CHIKV ELISA (IgM, IgG)^c^: 0/19 (0%) anti-CHIKV IgM positive, 19/19 (100%) anti-CHIKV IgG positive

  **Parasite infection**                                                                                                                                                                                                                                                                                                                                                                                                                     

  PLAS                                                              69    France (including overseas department and region Mayotte), French Guiana, Tunisia, Madagascar, Switzerland   Blood donors living in and travellers returning from *Plasmodium*-endemic areas, acute or past *Plasmodium* infection                                 TheBindingSite, Schwetzingen, Germany\                                         2016             • BioMérieux Plasmodium IFA (IgM, IgG)^d,h^: 1/15 (7%) anti-*Plasmodium* IgM positive, 15/15 (100%) anti-*Plasmodium* IgG positive\
                                                                                                                                                                                                                                                                                                                                             Cerba Specimen Services, Saint-Ouen l'Aumône, France\                                           • BIO-RAD Malaria ELISA (IgG)^i^: 54/54 (100%) anti-*Plasmodium* positive
                                                                                                                                                                                                                                                                                                                                             Swiss Red Cross, Bern, Switzerland                                                              

  **Healthy controls: pregnant women, blood donors and children**                                                                                                                                                                                                                                                                                                                                                                            

  PREG                                                              100   Germany                                                                                                      Pregnant women from non-flavivirus endemic areas without clinical symptoms                                                                            Laboratory Schottdorf, Augsburg, Germany                                       2007             • EUROIMMUN Anti-DENV ELISA (IgM, IgG)^c^: 2/100 (2%) anti-DENV IgM positive, 7/100 (7%) anti-DENV IgG positive\
                                                                                                                                                                                                                                                                                                                                                                                                                                             • EUROIMMUN Anti-WNV ELISA (IgM, IgG)^c^ 3/100 (3%) anti-WNV IgM positive, 4/100 (4%) anti-WNV IgG positive\
                                                                                                                                                                                                                                                                                                                                                                                                                                             • EUROIMMUN Anti-JEV ELISA (IgM, IgG)^c^: 2/100 (2%) anti-JEV IgM positive, 14/100 (14%) anti-JEV IgG positive\
                                                                                                                                                                                                                                                                                                                                                                                                                                             • EUROIMMUN Anti-CHIKV ELISA (IgM, IgG)^c^: 0/100 (0%) anti-CHIKV IgM positive, 0/100 (0%) anti-CHIKV IgG positive

  ZIM                                                               128   Zimbabwe                                                                                                     Blood donors from flavivirus and parasite endemic areas without clinical symptoms                                                                     National Blood Transfusion Service, Zimbabwe, Africa                           2003             • EUROIMMUN Anti-DENV ELISA (IgG)^c^: 4/128 (3%) anti-DENV IgG positive\
                                                                                                                                                                                                                                                                                                                                                                                                                                             • EUROIMMUN Anti-CHIKV ELISA (IgG)^c^: 3/128 (2%) anti-CHIKV IgG positive\
                                                                                                                                                                                                                                                                                                                                                                                                                                             • EUROIMMUN Anti-Plasmodium ELISA (IgG)^c^: 36/128 (28%) anti-*Plasmodium* IgG positive

  ARG                                                               99    Argentina                                                                                                    Blood donors from flavivirus endemic areas without signs of viral infection (routine samples for parasitology)                                        IACA Laboratory, Buenos Aires, Argentina                                       2014             • EUROIMMUN Anti-DENV ELISA (IgM, IgG)^c^: 2/99 (2%) anti-DENV IgM positive, 4/99 (4%) anti-DENV IgG positive\
                                                                                                                                                                                                                                                                                                                                                                                                                                             • EUROIMMUN Anti-WNV ELISA (IgM, IgG)^c^: 2/99 (2%) anti-WNV IgM positive, 3/99 (3%) anti-WNV IgG positive\
                                                                                                                                                                                                                                                                                                                                                                                                                                             • EUROIMMUN Anti-CHIKV ELISA (IgM, IgG)^c^: 3/99 (3%) anti-CHIKV IgM positive, 1/99 (1%) anti-CHIKV IgG positive\
                                                                                                                                                                                                                                                                                                                                                                                                                                             • EUROIMMUN Anti-Trypanosoma ELISA (IgM, IgG)^c^: 2/99 (2%) anti-Trypanosoma IgM positive, 1/99 (1%) anti-Trypanosoma IgG positive

  US                                                                100   US                                                                                                           Blood donors without clinical symptoms (n): Hispanic (25), African American (30), Caucasian (43), Asian (1), Colombian (1)                            Serologix, New Hope, Pasadena, US                                              2014             • EUROIMMUN Anti-DENV ELISA (IgM, IgG)^c^: 1/100 (1%) anti-DENV IgM positive, 6/100 (6%) anti-DENV IgG positive\
                                                                                                                                                                                                                                                                                                                                                                                                                                             • EUROIMMUN Anti-WNV ELISA (IgM, IgG)^c^: 0/100 (0%) anti-WNV IgM positive, 4/100 (4%) anti-WNV IgG positive\
                                                                                                                                                                                                                                                                                                                                                                                                                                             • EUROIMMUN Anti-CHIKV ELISA (IgM, IgG)^c^: 0/100 (0%) anti-CHIKV IgM positive, 4/100 (4%) anti-CHIKV IgG positive

  GER                                                               500   Germany                                                                                                      Blood donors from non-flavivirus endemic areas without clinical symptoms                                                                              University Medical Center Schleswig-Holstein, Campus Lübeck, Lübeck, Germany   2012             NA

  CHIL                                                              88    Germany                                                                                                      Children (≤ 10 years) form non-flavivirus endemic areas without clinical symptoms                                                                     Praxis Dr Fischer-Wassels, Dortmund, Germany                                   2007--2008       • EUROIMMUN Anti-DENV ELISA (IgM, IgG)^c^: 0/100 (0%) anti-DENV IgM positive, 0/100 (0%) anti-DENV IgG positive\
                                                                                                                                                                                                                                                                                                                                                                                                                                             • EUROIMMUN Anti-WNV ELISA (IgM, IgG)^c^: 1/100 (1%) anti-WNV IgM positive, 0/100 (0%) anti-WNV IgG positive\
                                                                                                                                                                                                                                                                                                                                                                                                                                             • EUROIMMUN Anti-JEV ELISA (IgM, IgG)^c^: 0/100 (0%) anti-JEV IgM positive, 0/100 (0%) anti-JEV IgG positive\
                                                                                                                                                                                                                                                                                                                                                                                                                                             • EUROIMMUN Anti-CHIKV ELISA (IgM, IgG)^c^: 0/100 (0%) anti-CHIKV IgM positive, 0/100 (0%) anti-CHIKV IgG positive
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ARG: Argentina; CHIKV: chikungunya virus; CHIL: children; DENV: dengue virus; IFA: immunofluorescence assay; GER: Germany; JEV: Japanese encephalitis virus; IIFA: indirect immunofluorescence assay; NA: not available; PLAS: *Plasmodium*; PREG: pregnant women; PRNT: plaque reduction neutralisation test; RT-PCR: reverse transcription-PCR; US: United States; WHOCC: World Health Organization Collaborating Centre (for Arbovirus and Haemorrhagic Fever Reference and Research); WNV: West Nile virus; YFV: yellow fever virus; ZIKV: Zika virus; ZIM: Zimbabwe.

^a^ Performed at MVZ Diamedis GmbH, Bielefeld, Germany.

^b^ Performed at the University of Bologna, Italy.

^c^ Performed at EUROIMMUN, Lübeck, Germany.

^d^ Performed at Cerba Specimen Services, Saint-Ouen l\'Aumône, France.

^e^ Performed at the University of Leipzig, Germany.

^f^ Performed at the National Hospital of Tropical Disease, Hanoi, Vietnam.

^g^ Performed at the University of Bonn, Germany.

^h^ Performed at TheBindingSite, Schwetzingen, Germany.

^i^ Performed at the Swiss Red Cross, Bern, Switzerland.

Specimens, anamnestic/clinical information and pre-characterisation data were provided anonymised to the Institute for Experimental Immunology (affiliated to EUROIMMUN). All sera were stored at -20 °C until assayed. The study was performed according to the recommendations of the Central Ethical Committee of Germany \[[@r29]\].

Enzyme-linked immunosorbent assays
----------------------------------

Anti-Zika Virus IgM and IgG ELISA (EUROIMMUN) were used as recommended by the manufacturer. These kit assays are based on standardised reagents and microtitre plates coated with recombinant ZIKV-NS1. Briefly, sera diluted 1:101 in sample buffer were added to the wells and allowed to react for 60 min at 37 °C. Before IgM detection, sera were pre-incubated with sample buffer containing IgG/rheumatoid factor (RF) absorbent (EUROIMMUN) to remove class IgG antibodies and class IgM RF from the sample. This step prevents specific IgG from displacing IgM from the antigen (leading to false IgM-negative results) and RF-IgM from reacting with specifically bound IgG (leading to false IgM-positive results). Bound antibodies were detected by applying goat anti-human IgM peroxidase conjugate or rabbit anti-human IgG peroxidase conjugate for 30 min at room temperature, followed by staining with tetramethylbenzidine for 15 min. The enzymatic reaction was stopped by addition of one volume 0.5 mol/L sulphuric acid. A calibrator (chicken--human chimeric ZIKV antibody with a concentration adjusted to give an extinction value defining the upper limit of the reference range of non-infected persons) as well as positive and negative controls were provided with the test kit and assayed with each test run. Colour intensity of the enzymatic reactions was determined photometrically at 450 nm (reference 620 nm), resulting in extinction values. A signal-to-cut-off ratio (extinction~sample~/extinction~calibrator~) was calculated for each sample.

Receiver-operating characteristics (ROC) analysis based on the initial validation dataset of positive and negative samples was done by the manufacturer to evaluate assay performance at each possible cut-off, demonstrating optimal sensitivity and specificity at ratio values of 0.8 (IgM) and 0.6 (IgG). To ensure high specificity, the borderline range (≥ 0.8 to \< 1.1) was established between the highest negative and the lowest positive validation sample, resulting in a positivity cut-off of ≥ 1.1.

Anti-dengue Virus IgM and IgG ELISA (EUROIMMUN) were used.

Statistics
----------

Statistical analyses were performed using GraphPad Prism 6 (GraphPad Software Inc., La Jolla, California, US) and SigmaPlot 13.0 (SSI, San Jose, California, US). Sensitivity was calculated as the proportion of ZIKV patients (referring to groups 1 to 4 as indicated) identified as positive by the assay. Specificity was calculated as the proportion of negative test results obtained among healthy controls. We calculated 95% confidence intervals (CIs) according to the modified Wald method. The study was performed in compliance with the Standards for Reporting of Diagnostic accuracy (STARD) statement \[[@r30]\].

Results
=======

Sensitivity of the enzyme-linked immunosorbent assay
----------------------------------------------------

The sensitivity of the novel NS1-based anti-ZIKV ELISA was evaluated in sera from 27 patients with RT-PCR-confirmed ZIKV infection that had been sub-grouped into travellers returning from ZIKV-endemic areas and endemic-area residents. Among eight infected travellers returning from ZIKV-endemic areas (group 1), positive anti-ZIKV IgM and IgG reactivity was found in seven (87.5%) and three (37.5%) cases, respectively. Of 19 infected residents in endemic-areas (group 2), six (31.6%) were positive for anti-ZIKV IgM and 15 (79.0%) for IgG. In addition, sera from 85 patients with suspected ZIKV infection were examined. Here, of 26 infected travellers returning from ZIKV-endemic areas (group 3) 21 (80.8%) were positive for anti-ZIKV IgM and 18 (69.2%) for IgG, while among 59 infected residents in endemic-areas (group 4), six (10.2%) showed positive reactivity for anti-ZIKV IgM and 53 (89.9%) for IgG. For the total of RT-PCR-confirmed and suspected cases, the combined ELISA sensitivity (IgM and/or IgG) amounted to 23/27 (85.2%) and 78/85 (91.8%), respectively.

Confining the time point of serological evaluation to the active and late phase of ZIKV infection, i.e. ≥ 6 days after symptom onset, anti-ZIKV IgM reactivity was observed in 10/17 (58.8%) patients with positive ZIKV-RT-PCR and 3/38 (7.9%) patients with suspected ZIKV infection, while anti-ZIKV IgG was detectable in 15/17 (88.2%) and 34/38 (89.5%) cases, respectively. Thus, the combined sensitivity (IgM and/or IgG) reached 17/17 (100%) among RT-PCR-confirmed cases and 34/38 (89.5%) among suspected cases ([Table 3](#t3){ref-type="table"}).

###### Anti-ZIKV reactivity in patients with RT-PCR-confirmed (n = 27) and suspected (n = 85) ZIKV infection as determined by ELISA for IgM and IgG, study evaluating a novel NS1-based ELISA, Germany 2016

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
        Group          Characteristics                                                                                Anti-ZIKV ELISA reactivity\       Anti-ZIKV ELISA reactivity\                                                                                     
                                                                                                                      (≥ 1 day post symptom onset)^c^   (≥ 6 days post symptom onset)^d,e^                                                                              
  -------------------- ------------------------------------------------------------------------------- -------------- --------------------------------- ------------------------------------ -------------- -------------- -------------- -------------- -------------- ----
  1                    RT-PCR-confirmed ZIKV infection, travellers returning from ZIKV-endemic areas   Positive       8                                 7                                    3              7              5              5              3              5

  Sensitivity %^b^\    --                                                                              87.5\          37.5\                             87.5\                                --             100\           60.0\          100\                          
  (95% CI)                                                                                             (50.8--99.9)   (13.5--69.6)                      (50.8--99.9)                                        (51.1--100)    (22.9--88.4)   (51.1--100)                   

  2                    RT-PCR-confirmed ZIKV infection, residents in ZIKV-endemic areas^a^             Positive       19                                6                                    15             16             12             5              12             12

  Sensitivity %^b^\    --                                                                              31.6\          78.9\                             84.2\                                --             41.7\          100\           100\                          
  (95% CI)                                                                                             (15.2--54.2)   (56.1--92.1)                      (61.6--95.3)                                        (19.3--68.1)   (71.8--100)    (71.8--100)                   

  Total 1 + 2          RT-PCR-confirmed ZIKV infection                                                 Positive       27                                13                                   18             23             17             10             15             17

                       Sensitivity %^b^\                                                               --             48.1\                             66.7\                                85.2\          --             58.8\          88.2\          100\           
                       (95% CI)                                                                                       (30.7--66.0)                      (47.7--81.5)                         (66.9--94.7)                  (36.0--78.4)   (64.4--98.0)   (78.4--100)    

  3                    Suspected ZIKV infection, travellers returning from ZIKV-endemic areas          Positive       26                                21                                   18             25             NA^e^\                                       

  Sensitivity %^b^\    --                                                                              80.8\          69.2\                             96.2\                                                                                                           
  (95% CI)                                                                                             (61.7--92.0)   (49.9--83.7)                      (79.6--100)                                                                                                     

  4                    Suspected ZIKV infection, residents ZIKV-endemic areas                          Positive       59                                6                                    53             53             38             3              34             34

  Sensitivity %^b^\    --                                                                              10.2\          89.9\                             89.9\                                --             7.9\           89.5\          89.5\                         
  (95% CI)                                                                                             (4.4--20.8)    (79.2--95.6)                      (79.2--95.6)                                        (2.0--21.5)    (75.3--96.4)   (75.3--96.4)                  

  Total 3 + 4          Suspected ZIKV infection                                                        Positive       85                                27                                   71             78             38^e^          3              34             34

                       Sensitivity %^b^\                                                               --             31.8\                             83.5\                                91.8\          --             7.9\           89.5\          89.5\          
                       (95% CI)                                                                                       (22.8--42.3)                      (74.1--90.1)                         (83.7--96.2)                  (2.0--21.5)    (75.3--96.4)   (75.3--96.4)   
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CI: confidence interval; NA: not available or not applicable; NS: non-structural protein; RT-PCR: reverse transcription-PCR; ZIKV: Zika virus.

^a^ This group contains 10 sera from residents of the Netherlands who were born and raised in Suriname and/or had visited their country of origin occasionally.

^b^ Referring to the total number of samples in the respective patient group during the indicated sampling period.

^c^ Referring to the whole study population of ZIKV-infected patients, i.e. samples (one per patient) taken between day 1 and day 88 post symptom onset, representing the initial (day 1--5 post symptom onset), active (day 6--20) and late phase (\> 20 days) of infection.

^d^ Samples (one per patient) taken between day 6 and day 88 post symptom onset, representing the active (day 6 to 20 post symptom onset) and late phase (\> 20 days post symptom onset) of infection \[[@r28]\].

^e^ Group 3 is not represented in the sampling period ≥ 6 days post symptom onset, because the sampling date was available for only four out of a total of 26 samples in this group.

Comparing ZIKV-infected travellers returning from endemic areas (groups 1 and 3) with infected residents in these areas (groups 2 and 4), a tendency of distinct ZIKV antibody kinetics could be observed: in most returning travellers, high IgM ratio values (median 5.6; interquartile range (IQR): 4.6--6.9,) and moderate IgG ratios (median 2.2; IQR 0.9--2.8,) were detectable in the active phase of infection (cut-off ratio: 1.1). By contrast, the majority of endemic-area residents had infections with very high IgG ratios (median 4.8; IQR 3.3--5.9) during the active phase, while IgM ratios were variable, but predominantly negative or low (median 0.5; IQR 0.2--1.3) ([Figure 1A](#f1){ref-type="fig"} and [1B](#f1){ref-type="fig"}).

![Anti-ZIKV reactivity in patients with RT-PCR-confirmed (n = 27) and suspected (n = 85) ZIKV infection as determined by ELISA for (A) IgM and (B) IgG^a^; time course analysis of anti-ZIKV antibody levels in follow-up samples from (C) a German patient returning from Colombia (probable primary ZIKV infection)^b^ and (D) a Colombian patient with RT-PCR-confirmed ZIKV infection (probable secondary flavivirus infection)^c^](eurosurv-21-30426-f1){#f1}

Time course analysis of a German patient who showed clinical symptoms after returning from a stay in Colombia revealed very high anti-ZIKV IgM ratios on first testing (day 10 after symptom onset), while IgG ratios increased to moderate levels during the acute phase of infection and thereafter ([Figure 1C](#f1){ref-type="fig"}). On the other hand, follow-up samples taken from a Colombian resident with RT-PCR-confirmed ZIKV infection indicated a significant rise in the ZIKV-specific IgG response between days 3 and 15 after symptom onset, followed by a slow decrease, while anti-ZIKV IgM was negative 3 days after symptom onset and remained below detection threshold for 14 weeks ([Figure 1D](#f1){ref-type="fig"}).

Cross-reactivity of the enzyme-linked immunosorbent assay
---------------------------------------------------------

Cross-reactivity was analysed first in sera from 93 DENV-infected patients whose diagnosis had been secured by positive DENV-NS1 detection. This cohort was divided into one group (DENVa) with high anti-DENV IgM (median ratio 3.9) and another group (DENVb) with high anti-DENV IgG (median ratio 3.9), ensuring the presence of high levels of potentially cross-reactive antibodies. In both groups, anti-ZIKV reactivity was below the threshold, indicating absence of cross-reactivity in these specimens. Further testing, on a supplementary basis, included 159 sera from patients positive for IgM and/or IgG against YFV, WNV, JEV, CHIKV or PLAS. Anti-ZIKV IgM was positive in 1/34 (2.9%) patients infected with WNV and 1/69 (1.4%) patients infected with PLAS. Anti-ZIKV IgG was found in 1/25 (4.0%) patients infected with JEV ([Figure 2](#f2){ref-type="fig"}). For the total of 252 potentially cross-reactive samples, the overall positivity rate amounted to 2/252 (0.8%) for IgM and 1/252 (0.4%) for IgG ([Table 4](#t4){ref-type="table"}).

![Anti-ZIKV reactivity in potentially cross-reactive samples (n = 252) and healthy controls (n = 1,015) as determined by ELISA for (A) IgM and (B) IgG^a,b^, study evaluating a novel NS1-based ELISA, Germany 2016\*](eurosurv-21-30426-f2){#f2}

###### Anti-ZIKV reactivity in potentially cross-reactive specimens (n = 252) and healthy controls (n = 1,015) as determined by ELISA for IgM and IgG, study evaluating a novel NS1-based ELISA, Germany 2016

  Cohort   Characteristics                                                 Prevalence % (CI 95%)^c^   Specificity (CI 95%)^c^                      
  -------- ------------------------------------------------------- ------- -------------------------- ------------------------- ------------------ ------------------
  DENVa    Dengue virus infection (high median anti-DENV IgM)^a^   47      0 (0--9.0)                 0 (0--9.0)                100 (91.0--100)    100 (91.0--100)
  DENVb    Dengue virus infection (high median anti-DENV IgG^b^    46      0 (0--9.2)                 0 (0--9.2)                100 (90.8--100)    100 (90.8--100)
  YFV      Yellow fever virus vaccination                          12      0 (0--28.2)                0 (0--28.2)               100 (71.8--100)    100 (71.8--100)
  WNV      West Nile virus infection                               34      2.9 (0--16.2)              0 (0--12.1)               97.1 (83.8--100)   100 (87.9--100)
  JEV      Japanese encephalitis virus infection                   25      0 (0--15.8)                4.0 (0--21.1)             100 (84.2--100)    96.0 (78.9--100)
  CHIKV    Chikungunya virus infection                             19      0 (0--19.8)                0 (0--19.8)               100 (80.2--100)    100 (80.2--100)
  PLAS     *Plasmodium* spp. Infection                             69      1.4 (0--8.5)               0 (0--6.3)                98.6 (91.5--100)   100 (93.7--100)
  Total    Potentially cross-reactive samples                      252     0.8 (0--3.0)               0.4 (0--2.4)              99.2 (97.0--100)   99.6 (97.6--100)
  PREG     German pregnant women                                   100     0 (0--4.4)                 0 (0--4.4)                100 (95.6--100)    100 (95.6--100)
  ZIM      Zimbabwean blood donors                                 128     0 (0--3.5)                 0 (0--3.5)                100 (96.5--100)    100 (96.5--100)
  ARG      Argentinian blood donors                                99      1.0 (0--6.1)               0 (0--4.5)                99.0 (94.0--100)   100 (95.5--100)
  US       US-American blood donors                                100     0 (0--4.4)                 1.0 (0--6.0)              100 (95.6--100)    99.0 (94.0--100)
  GER      German blood donors                                     500     0.2 (0--1.2)               0.2 (0--1.2)              99.8 (98.8--100)   99.8 (98.8--100)
  CHIL     German children                                         88      0 (0--5.0)                 0 (0--5.0)                100 (95.0--100)    100 (95.0--100)
  Total    Healthy control samples                                 1,015   0.2 (0--0.8)               0.2 (0--0.8)              99.8 (99.2--100)   99.8 (99.2--100)

ARG: Argentina; CHIKV: chikungunya virus; CHIL: children; DENV: dengue virus; GER: Germany; JEV: Japanese encephalitis virus; PLAS: *Plasmodium*; PREG: pregnant women; US: United States; WNV: West Nile virus; YFV: yellow fever virus; ZIKV: Zika virus; ZIM: Zimbabwe.

^a^ Median anti-DENV IgM ratio 3.9 (79% of samples with anti-DENV IgM ratio ≥ 3.0), as indicated in the inset of [Figure 2A](#f2){ref-type="fig"}.

^b^ Median anti-DENV IgG ratio 3.9 (80% of samples with anti-DENV IgG ratio ≥ 3.0), as indicated in the inset of [Figure 2B](#f2){ref-type="fig"}.

^c^ Referring to the total number of samples in the individual cohorts.

Specificity of the enzyme-linked immunosorbent assay
----------------------------------------------------

Assay specificity was assessed by testing 1,015 sera from healthy controls. Only 1/99 (1.0%) Argentinian and 1/500 (0.2%) German blood donors were found anti-ZIKV IgM positive, while all 128 Zimbabwean and 100 US American blood donors as well as 100 German pregnant women and 88 children in Germany were negative. Anti-ZIKV IgG was present in 1/100 (1.0%) US American and 1/500 (0.2%) German blood donors, but absent in the cohorts of Zimbabwean and Argentinian blood donors, pregnant women and children. Thus, overall specificity amounted to 99.8% for either Ig class ([Table 4](#t4){ref-type="table"}, [Figure 2](#f2){ref-type="fig"}).

Discussion
==========

The serological diagnosis of ZIKV infections has been challenging due to cross-reactions with other flaviviruses, secondary infections and previous vaccinations, which complicate interpretation, sometimes leading to unreliable or false-positive results \[[@r6],[@r31],[@r32]\]. Here, we evaluated a newly-developed ELISA with recombinant ZIKV-NS1 protein as solid-phase antigen. Huzly et al. recently provided evidence that this assay is highly specific, as demonstrated on a limited number of European patients with DENV, YFV, tick-borne encephalitis virus (TBEV) or hepatitis C virus infection \[[@r27]\]. In the present study, testing on specimens collected ≥ 6 days after onset of symptoms (i.e. after the viraemic phase) revealed a combined sensitivity (IgM/IgG) of 100% for RT-PCR-confirmed cases of ZIKV infection at 99.8% specificity. Among suspected ZIKV cases, the combined sensitivity amounted to 89.5%. Notably, we included only one serum sample for each of the studied patients in our analysis, except for the time course analysis. For the serological diagnosis of patients, however, the evaluation of follow-up samples is important and recommended to demonstrate seroconversion or a 4-fold increase in antibody titre \[[@r28]\]. In four of 27 RT-PCR-confirmed ZIKV cases, samples were negative for both IgM and IgG against ZIKV-NS1, presumably because all of them were taken only ≤ 4 days after symptom onset, i.e. when antibodies had not yet reached detectable levels. Among 85 suspected ZIKV patients, too early sampling may account for two cases with negative IgM and IgG, while the remaining five double-negative cases could be due to the absence of ZIKV infection (deficits in pre-characterisation) or to false-negative results.

Cross-reactivity with high-level DENV antibodies was not detectable and, according to preliminary analysis with a limited amount of samples, there was no indication for DENV serotype-dependent differences in cross-reactivity (data not shown). To better judge assay performance in endemic areas, samples from endemic residents who experienced multiple DENV (and other flavivirus) infections should be included in further assessments, as these samples have a potential for increased cross-reactivity. Future studies should also address a comparison of cross-reactivity with acute vs convalescent anti-DENV-positive samples, considering that the extent of cross-reactivity may be influenced by the level of circulating DENV-NS1 antigen-binding DENV-NS1 antibodies. Analysis of all potentially cross-reactive specimens resulted in positive rates of 0.8% (IgM) and 0.4% (IgG) caused by one case each with WNV and PLAS with low-level anti-ZIKV IgM and one JEV case with low-level anti-ZIKV IgG. In these cases, however, double infections cannot be excluded, so it remains unclear if ELISA positivity resulted from the presence of ZIKV antibodies due to co-infection with ZIKV (true-positive) or from cross-reactivity (false-positive). In case of PLAS infection, PLAS-induced polyclonal B-cell activation may cause the production of potentially cross-reactive antibodies \[[@r33]\]. Among patients with current PLAS infection, up to 30% false-positive or borderline reactions were reported using the presented NS1-based ELISA \[[@r34]\], which is in contrast to only 1.4% in the present study and probably explained by the fact that our cohort was comprised mainly of individuals with past PLAS infection status. Possible interferences should thus be considered when applying the assay.

In sera from travellers returning from ZIKV-endemic areas, we observed a tendency of ZIKV-specific IgM to appear at high ratios during the active phase of infection, paralleled by a moderate rise in IgG. In contrast, most residents in endemic areas had high anti-ZIKV IgG and low/negative IgM ratio values, irrespective of whether their samples were taken during the initial, active or late phase of infection. IgM responses in travellers returning from ZIKV-endemic areas tended to be higher compared with residents in such areas, whereas the IgG-positivity rate was higher in the latter subgroup. Such differences in ZIKV antibody kinetics were also illustrated by time course analysis of antibody levels in two representative patients, possibly reflecting that travellers returning from ZIKV-endemic countries predominantly had a primary flavivirus/ZIKV infection, while most residents probably contracted ZIKV as a secondary flavivirus infection. Similar kinetics have been described for primary and secondary infections in the Micronesian ZIKV epidemic \[[@r6]\] and for DENV-infected patients \[[@r35],[@r36]\], suggesting that the detection of both specific IgM and IgG is diagnostically important and relevant for differentiating primary from secondary infections. Regarding our comparison of patients residing in endemic countries vs travellers, however, systematic differences in the background of these populations (e.g. genetic, ethnic) cannot be excluded.

Another limitation of our study is that it does not comprise side-by-side testing with additional assays, such as the Zika MAC-ELISA (Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, US) or PRNT, to provide comparative data on these current tests. In addition, the non-deliberate absence of a uniform serological reference standard for the pre-characterisation of all ZIKV samples resulted in a high number of suspected cases of ZIKV infection.

Although ZIKV usually causes rather mild infections, there has been convincing evidence of a causal link to neuronal impairment, such as newborn microcephaly and GBS \[[@r37]\]. Furthermore, there have been studies showing that DENV NS1 antibodies have the potential of inducing autoantibodies in secondary infections, probably mediated by cross-reactive binding of antigens on platelets and endothelial cells, followed by cellular damage and inflammatory activation \[[@r17]\]. Basic research is needed to fully elucidate the causal relations between neuronal disorders and ZIKV infection. Epidemiologic assessment of pregnant women and their babies, and of travellers returning from endemic areas, the surveillance of donated blood and the investigation of ZIKV prevalence in endemic and non-endemic areas may provide crucial information. These studies need reliable, fast, and easy-to-handle diagnostic tests that have low cross-reactivity and allow a definite diagnosis.

In conclusion, our study revealed that the NS1-based anti-ZIKV ELISA is a sensitive and highly specific tool for the serodiagnosis of ZIKV infections, eliminating cross-reactions with antibodies to DENV and other flaviviurses. The assay format is suitable for use in routine laboratories worldwide enabling high-throughput testing in epidemic settings. Serological identification of ZIKV infections is maximised by parallel testing for IgM and IgG. Further studies will be necessary to determine the accuracy of this and other current assays in a larger set of well-defined samples, and to clarify how ZIKV infection triggers GBS, newborn microcephaly and other neurological manifestations.
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\*Erratum
=========

The title of the y-axis in Figure 2B was corrected to read 'Anti-Zika virus IgG ELISA (ratio)' on 22 December 2016.
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